Nkarta (NKTX) Cash from Investing Activities (2019 - 2026)
Nkarta's (NKTX) quarterly Cash from Investing Activities came in at $15.9 million in Q1 2026, down 70.71% year-on-year from $54.3 million in Q1 2025, and up 1342.88% quarter-over-quarter from $1.1 million in Q4 2025.
Nkarta (NKTX) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Nkarta's Cash from Investing Activities history runs 8 years deep, the most recent figure standing at $15.9 million for Q1 2026.
- On a quarterly basis, Cash from Investing Activities fell 70.71% year-over-year to $15.9 million in Q1 2026; TTM through Mar 2026 was $61.9 million, a 164.01% increase from a year earlier, with the FY2025 full-year figure at $100.3 million, up 177.43% from the prior year.
- Cash from Investing Activities improved to $15.9 million in Q1 2026 per NKTX's latest filing, from $1.1 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $54.3 million in Q1 2025 and bottomed at -$109.3 million in Q2 2022.
- The 5-year median for Cash from Investing Activities is $4.7 million (2022), against an average of -$7.0 million.
- Across the five-year window, Cash from Investing Activities jumped 3699.32% in 2023 and plunged 3294.04% in 2024, its largest moves.
- Year by year, Cash from Investing Activities stood at $4.7 million in 2022, then soared by 233.62% to $15.8 million in 2023, then plunged by 128.54% to -$4.5 million in 2024, then soared by 124.4% to $1.1 million in 2025, then surged by 1342.88% to $15.9 million in 2026.
- Per Business Quant, the three latest NKTX Cash from Investing Activities figures stand at $15.9 million (Q1 2026), $1.1 million (Q4 2025), and $25.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Nkarta | 168.94 Mn | 168.94 Mn | - | 15.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.92 Mn |
| Mar 31, 2026 | 15.92 Mn |
| Dec 31, 2025 | 1.10 Mn |
| Dec 31, 2025 | 1.10 Mn |
| Sep 30, 2025 | 25.39 Mn |
| Sep 30, 2025 | 25.39 Mn |
| Jun 30, 2025 | 19.49 Mn |
| Jun 30, 2025 | 19.49 Mn |
| Mar 31, 2025 | 54.34 Mn |
| Mar 31, 2025 | 54.34 Mn |
| Dec 31, 2024 | -4.52 Mn |
| Dec 31, 2024 | -4.52 Mn |
| Sep 30, 2024 | -38.90 Mn |
| Sep 30, 2024 | -38.90 Mn |
| Jun 30, 2024 | -107.63 Mn |
| Jun 30, 2024 | -107.63 Mn |
| Mar 31, 2024 | 21.49 Mn |
| Mar 31, 2024 | 21.49 Mn |
| Dec 31, 2023 | 15.84 Mn |
| Dec 31, 2023 | 15.84 Mn |